A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic Esophagitis
Part of paid clinical trials in Phoenix, Arizona.
- Sponsor
- Regeneron Pharmaceuticals
- Study ID
- NCT07112378
- Phase
- PHASE3
- Status
- Recruiting
Conditions
- Eosinophilic Esophagitis (EoE)
Eligibility Criteria
- Sex
- ALL
- Age
- 6 Months - 6 Years
- Healthy Volunteers
- Not accepted
Interventions
- dupilumab — DRUGAdministered as defined in the protocol
Study Details
This study is researching an experimental drug called dupilumab (called "study drug"). The study is focused on children with active eosinophilic esophagitis (EoE; an inflammatory disease of the esophagus) which impacts feeding and nourishment. The aim of the study is to see how safe, tolerable, and effective the study drug is when given for 24 weeks to children with active EoE. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
Key Dates
- Start date
- Nov 10, 2025
- Status verified
- May 2026
- Primary completion
- Jun 19, 2028
- Completion
- Oct 9, 2028
Study Design
- Enrollment
- 20 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Dosing Regimen 1
- Experimental: Dosing Regimen 2
Primary Outcome Measure
Incidence of treatment-emergent Serious Adverse Events (SAEs) [ Time Frame: Up to 24 Weeks ]
Central Contacts
- Clinical Trials Administrator844-734-6643
Locations (10)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Phoenix Childrens Hospital | Phoenix | Arizona | 85016 | - |
| Children's Hospital Colorado | Aurora | Colorado | 80045 | - |
| GI Care for Kids LLC | Atlanta | Georgia | 30342 | - |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | - |
| Weill Cornell Medicine | New York | New York | 10065 | - |
| University of North Carolina, Bioinformatics Building | Chapel Hill | North Carolina | 27599 | - |
| Children's Hospital of Philadelphia | Philadelphia | Pennsylvania | 19104 | - |
| Medical University of South Carolina | Charleston | South Carolina | 29425 | - |
| Cook Children's Medical Center | Fort Worth | Texas | 76104 | - |
| University of Virginia | Charlottesville | Virginia | 22908 | - |
Find similar trials in Phoenix, AZ
Related Studies
- Esophageal String Test Monitoring to Monitor Eosinophilic Esophagitis During Oral ImmunotherapyRecruiting · Children's Hospital of Philadelphia · Philadelphia, Pennsylvania
- A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of CareRecruiting · Regeneron Pharmaceuticals · Phoenix, Arizona
- Comparison of Eohilia With Dupixent on Esophagus Diameter in Patients With Eosinophilic Esophagitis.EARLY_PHASE1 · Enrolling By Invitation · Mayo Clinic · Scottsdale, Arizona
- A Trial of Upadacitinib for Non-responsive Eosinophilic EsophagitisPHASE2 · Not Yet Recruiting · University of North Carolina, Chapel Hill · Chapel Hill, North Carolina